Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Hematol Oncol Clin North Am
; 33(2): 291-299, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30833001
ABSTRACT
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8+ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Linfócitos do Interstício Tumoral
/
Linfócitos T CD8-Positivos
/
Imunoterapia
/
Neoplasias
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Ano de publicação:
2019
Tipo de documento:
Article